Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Pharmacogenetic Assessment System
fda-device · Food and Drug Administration · Rule · Published 2025-08-21 · Effective 2025-08-21 · 90 FR 40704
Document
Document number
2025-16037
Federal Register citation
90 FR 40704
CFR reference
21 CFR 862
Type
Rule
Action
Final amendment; final order.
Category
fda-device
Sub-agency
Food and Drug Administration
Publication date
2025-08-21
Effective date
2025-08-21
HHS docket
Docket No. FDA-2025-N-2219
Abstract
The Food and Drug Administration (FDA, the Agency, or we) is classifying the pharmacogenetic assessment system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the pharmacogenetic assessment system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.